Last reviewed · How we verify
Neoadjuvant docetaxel + trastuzumab + pertuzumab (neoadjuvant-docetaxel-trastuzumab-pertuzumab)
Neoadjuvant docetaxel + trastuzumab + pertuzumab (generic name: neoadjuvant-docetaxel-trastuzumab-pertuzumab) is a Monoclonal antibody drug developed by Pfizer Inc.. It is currently in Phase 2 development.
At a glance
| Generic name | neoadjuvant-docetaxel-trastuzumab-pertuzumab |
|---|---|
| Sponsor | Pfizer Inc. |
| Modality | Monoclonal antibody |
| Phase | Phase 2 |
Approved indications
Common side effects
- Alopecia
- Nausea
- Diarrhoea
- Anaemia
- Neutropenia
- Fatigue
- Vomiting
- Leukopenia
- Asthenia
- NAUSEA
- ALOPECIA
- DIARRHOEA
Key clinical trials
- HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer (EARLY_PHASE1)
- A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer (PHASE3)
- ctDNA in HER2+ EBC Neoadjuvant Treatment (PHASE2)
- CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy (PHASE2)
- Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer (PHASE3)
- A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer (PHASE2)
- De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast Cancer (PHASE2)
- Diagnostic HER2DX-guided Treatment for Patients wIth Early-stage HER2-positive Breast Cancer (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Neoadjuvant docetaxel + trastuzumab + pertuzumab CI brief — competitive landscape report
- Neoadjuvant docetaxel + trastuzumab + pertuzumab updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI
Frequently asked questions about Neoadjuvant docetaxel + trastuzumab + pertuzumab
What is Neoadjuvant docetaxel + trastuzumab + pertuzumab?
Neoadjuvant docetaxel + trastuzumab + pertuzumab (neoadjuvant-docetaxel-trastuzumab-pertuzumab) is a Monoclonal antibody drug developed by Pfizer Inc..
Who makes Neoadjuvant docetaxel + trastuzumab + pertuzumab?
Neoadjuvant docetaxel + trastuzumab + pertuzumab is developed by Pfizer Inc. (see full Pfizer Inc. pipeline at /company/pfizer).
What is the generic name of Neoadjuvant docetaxel + trastuzumab + pertuzumab?
neoadjuvant-docetaxel-trastuzumab-pertuzumab is the generic (nonproprietary) name of Neoadjuvant docetaxel + trastuzumab + pertuzumab.
What development phase is Neoadjuvant docetaxel + trastuzumab + pertuzumab in?
Neoadjuvant docetaxel + trastuzumab + pertuzumab is in Phase 2.
What are the side effects of Neoadjuvant docetaxel + trastuzumab + pertuzumab?
Common side effects of Neoadjuvant docetaxel + trastuzumab + pertuzumab include Alopecia, Nausea, Diarrhoea, Anaemia, Neutropenia, Fatigue.
Related
- Manufacturer: Pfizer Inc. — full pipeline